↓ Skip to main content

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Overview of attention for article published in Cancer Immunology Research, March 2024
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
16 X users
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Published in
Cancer Immunology Research, March 2024
DOI 10.1158/2326-6066.cir-22-0306
Pubmed ID
Authors

Atish D. Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire, Jaqueline Marquez, David D. Yang, Abhishek Tripathi, Jacqueline M. Kilar, Meredith Flynn, Brianna Maynard, Rebecca Reichel, Amanda F. Pace, Brandon K. Chen, Eliezer M. Van Allen, Kerry Kilbridge, Xiao X. Wei, Bradley A. McGregor, Mark M. Pomerantz, Rupal S. Bhatt, Christopher J. Sweeney, Glenn J. Bubley, Heather A. Jacene, Mary-Ellen Taplin, Franklin W. Huang, Lauren C. Harshman, Lawrence Fong

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2024.
All research outputs
#3,336,955
of 25,758,211 outputs
Outputs from Cancer Immunology Research
#381
of 1,592 outputs
Outputs of similar age
#30,959
of 237,171 outputs
Outputs of similar age from Cancer Immunology Research
#3
of 21 outputs
Altmetric has tracked 25,758,211 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,592 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.1. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,171 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.